Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06082167 |
| Title | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305) |
| Acronym | STELLAR-305 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Exelixis |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | SVK | ROU | ITA | FRA | ESP | CZE | BRA | BGR | BEL | AUT | AUS | ARG |